ACB News, "Australia Finance Online" November 19, the biopharmaceutical company Starpharma Holdings Limited (ASX: SPL) announced today that it has conducted additional tests on its antiviral nasal spray active agent (SPL7013), and showed that SPL7013 It has strong antiviral activity against human respiratory syncytial virus (RSV). Respiratory syncytial virus is a common and highly infectious virus that can affect the lungs and respiratory tract. Approximately 64 million people worldwide are infected with the virus every year, causing 160,000 deaths.
SPL Price at posting:
$1.39 Sentiment: Buy Disclosure: Held
